Jupiter Neurosciences(JUNS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

JUNS Jupiter Neurosciences

Trading 06-01 09:56:32 EDT

0.2538

-0.0022

-0.86%

High0.2630	Low0.2500	Vol698.99K
Open0.2571	D1 Closing0.2560	Amplitude5.08%
Mkt Cap11.02M	Tradable Cap6.02M	Total Shares43.42M
T/O179.02K	T/O Rate2.94%	Tradable Shares23.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"JUNS","market":"US","secType":"STK","nameCN":"Jupiter Neurosciences","latestPrice":0.2538,"timestamp":1780322162928,"preClose":0.256,"halted":0,"volume":698987,"delay":0,"changeRate":-0.008593749999999921,"floatShares":23736200,"shares":43424100,"eps":-0.260986,"marketStatus":"Trading","change":-0.0022,"latestTime":"06-01 09:56:32 EDT","open":0.2571,"high":0.263,"low":0.25,"amount":179018.8187466,"amplitude":0.050781,"askPrice":0.2613,"askSize":100,"bidPrice":0.2502,"bidSize":97,"shortable":0,"etf":0,"ttmEps":-0.260986,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780344000000},"marketStatusCode":2,"adr":0,"listingDate":1733202000000,"exchange":"NASDAQ","adjPreClose":0.256,"preHourTrading":{"tag":"盘前","latestPrice":0.25,"preClose":0.256,"latestTime":"09:29 EDT","volume":228280,"amount":57532.44962400001,"timestamp":1780320576845,"change":-0.006,"changeRate":-0.023438,"amplitude":0.089844},"postHourTrading":{"tag":"盘后","latestPrice":0.2566,"preClose":0.256,"latestTime":"19:59 EDT","volume":324564,"amount":83929.10812,"timestamp":1780099185249,"change":0.0006,"changeRate":0.002344,"amplitude":0.035152},"volumeRatio":1.312915},"requestUrl":"/m/hq/s/JUNS","defaultTab":"news","newsList":[{"id":"2638500966","title":"Jupiter Neurosciences commences patient enrollment in RESET trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638500966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638500966?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:09","pubTimestamp":1779883757,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences (JUNS) announced that patient enrollment is now underway in its Phase 2a RESET clinical trial for Jotrol in Parkinson’s Disea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jupiter-neurosciences-commences-patient-enrollment-in-reset-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jupiter-neurosciences-commences-patient-enrollment-in-reset-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953502","title":"Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a Reset Trial in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638953502?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUAVCXGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JUNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357982","title":"Jupiter Neurosciences closes $2 million registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357982","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357982?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:15","pubTimestamp":1779398115,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences closed a registered direct offering of 7,142,858 common shares, raising gross proceeds of about $2 million.Proceeds extend cash runway to fund the company’s Parkinson’s program, including a planned Phase 2a trial.Part of the financing was used to reduce debt, improving the balance sheet and shareholder equity position.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL4dp53Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","SG9999014005.SGD","NDAQ","BK4585","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","LU2210150020.SGD","JUNS","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637576273","title":"Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637576273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637576273?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:15","pubTimestamp":1779398100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA69LSM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637542335","title":"Jupiter Neurosciences Inc - Files for Offering of 7.14 Mln Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2637542335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637542335?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:15","pubTimestamp":1779365753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637182788","title":"Jupiter Neurosciences prices registered direct offering at USD 2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637182788","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637182788?lang=en_us&edition=fundamental","pubTime":"2026-05-21 02:38","pubTimestamp":1779302292,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences priced a registered direct offering of 7,142,858 common shares for gross proceeds of about $2 million.Closing is expected on or about May 21, 2026, subject to customary conditions.D. Boral Capital is acting as exclusive placement agent.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL8WSDwd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","JUNS","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4112","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014039.USD","LU2210150020.SGD","BK4007","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637482200","title":"Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637482200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637482200?lang=en_us&edition=fundamental","pubTime":"2026-05-21 02:38","pubTimestamp":1779302280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUANZLZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636841927","title":"Jupiter Neurosciences Inc - to Buy Exclusive U.S. Rights to Ala-002 From Pharmala Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2636841927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636841927?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:38","pubTimestamp":1779277117,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0D7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JUNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636841908","title":"Jupiter Neurosciences agrees to pay $3.33 million for exclusive US rights to PharmAla’s ALA-002","url":"https://stock-news.laohu8.com/highlight/detail?id=2636841908","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636841908?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:38","pubTimestamp":1779277097,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences entered a term sheet to acquire exclusive, perpetual U.S. licensing rights to PharmAla Biotech’s ALA-002, a next-generation MDMA drug candidate.The deal values the upfront consideration at USD 3.33 million, split between USD 1.5 million in cash and USD 1.83 million in common stock, with additional development milestones and single-digit royalties.ALA-002 is a patented, non-racemic MDMA formulation that the FDA has recognized as a Novel Chemical Entity, with the companies citing improved cardiovascular safety and reduced abuse liability versus racemic MDMA.Jupiter agreed to place USD 600,000 into escrow on signing, credited against the upfront cash payment at closing.The parties target signing definitive agreements within 90 days, subject to due diligence and customary approvals.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL219rVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","JUNS","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","NDAQ","BK4585","BK4112","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635495729","title":"Jupiter Neurosciences Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $18.652K Miss $225.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635495729","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635495729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:10","pubTimestamp":1778793006,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences (NASDAQ:JUNS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 20 percent decrease over losses of $(0.05) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52583960/jupiter-neurosciences-q1-eps-0-06-misses-0-05-estimate-sales-18-652k-miss-225-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Jupiter Neurosciences Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $18.652K Miss $225.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729670","title":"Jupiter Neurosciences Q1 FY26 net loss widens 35% to $2.06 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729670?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:02","pubTimestamp":1778792532,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences posted a net loss of $2.06 million for quarter ended March 31, 2026, widening 35% from year-ago period.Net revenues were $18,652, swinging from no revenue a year earlier as Nugevia product shipments began in fourth-quarter 2025.General and administrative expense climbed 46% to $1.57 million, due to higher payroll and consulting costs plus expenses related to Nugevia.Research and development expense fell 12% to $411,049 on lower clinical trial and payroll and consulting costs.Cash and cash equivalents totaled $2.36 million at March 31, 2026, while net cash used in operating activities increased to $1.43 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL5JTPbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JUNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627929969","title":"Jupiter Neurosciences Inc - May Issue up to $100 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627929969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627929969?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:02","pubTimestamp":1776333774,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y14Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625958761","title":"Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2625958761","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625958761?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:00","pubTimestamp":1775563200,"startTime":"0","endTime":"0","summary":"New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3269087/0/en/Jupiter-Neurosciences-Appoints-Kristopher-Fishman-and-Sanjiv-Lal-to-Nugevia-Advisory-Board.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","JUNS","CNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624253565","title":"Jupiter Neurosciences Delays Annual 10-K Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624253565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624253565?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:43","pubTimestamp":1775090608,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences, Inc. ( ($JUNS) ) has released a notification of late filing. Jupiter Neurosciences, Inc. has filed a Form 12b-25 to notify i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jupiter-neurosciences-delays-annual-10-k-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jupiter-neurosciences-delays-annual-10-k-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624054120","title":"Jupiter Neurosciences FY25 net loss more than tripled to $8.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624054120","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624054120?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:46","pubTimestamp":1775076409,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences posted a fiscal 2025 net loss of USD 8.6 million.Revenue totaled USD 0 million on net sales of USD 0 million.Research and development expenses climbed to USD 2.1 million.General and administrative expenses rose to USD 6.8 million.FDA granted final IND approval in November 2025 for planned Phase IIa Parkinson’s study expected to start in Q2 2026, with results anticipated 12 months later.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6hGf0Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JUNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624117541","title":"Jupiter Neurosciences delays annual report filing after missing SEC cutoff time","url":"https://stock-news.laohu8.com/highlight/detail?id=2624117541","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624117541?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:38","pubTimestamp":1775075935,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences reported a delay in filing its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Company missed its March 31 filing deadline due to missing 5:30 p.m. ET filing cutoff.Management expects to file Form 10-K by April 1.Filing stated no significant change in results of operations is expected versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4xDBRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624753509","title":"Jupiter Neurosciences to Present at Emerging Growth Conference on April 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2624753509","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624753509?lang=en_us&edition=fundamental","pubTime":"2026-04-01 00:00","pubTimestamp":1774972800,"startTime":"0","endTime":"0","summary":"JUPITER, FL, March  31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL, a patented resverat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265840/0/en/Jupiter-Neurosciences-to-Present-at-Emerging-Growth-Conference-on-April-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4007","CNS","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332221","title":"Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332221","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332221?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:02","pubTimestamp":1772456561,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences Inc.  said it will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization , on March 2–3, 2026 in Miami Beach, Florida, with its corporate presentation scheduled for March 2, 2026 at 2:30 PM.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3mMh4V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210150020.SGD","BK4007","BK4585","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2095319765.USD","LU0314104364.USD","JUNS","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614589810","title":"Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2614589810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614589810?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:25","pubTimestamp":1772231140,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences, Inc. ( ($JUNS) ) has provided an update. On February 26, 2026, Jupiter Neurosciences disclosed it had received two Nasdaq de...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jupiter-neurosciences-receives-nasdaq-deficiency-notices-faces-delisting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jupiter-neurosciences-receives-nasdaq-deficiency-notices-faces-delisting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JUNS","BK4007","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614867662","title":"Nasdaq Flags Jupiter Neurosciences for Bid Price and Market Value Listing Deficiencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2614867662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614867662?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:33","pubTimestamp":1772228032,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences Inc. said it received Nasdaq notices that it is out of compliance with continued listing rules after its shares traded below the $1.00 minimum bid price for 30 consecutive business days and its market value of listed securities fell below the $35 million threshold over the same period. The company has until Aug. 25, 2026 to regain compliance with each requirement or potentially face delisting, though its stock will continue trading on the Nasdaq Capital Market in the meantime.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securitie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3dZ8ST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JUNS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jupiterneurosciences.com","stockEarnings":[{"period":"1week","weight":0.0765},{"period":"1month","weight":-0.2889},{"period":"3month","weight":-0.517},{"period":"6month","weight":-0.791},{"period":"1year","weight":-0.696},{"period":"ytd","weight":-0.749}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Jupiter Neurosciences","nameEN":"Jupiter Neurosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jupiter Neurosciences(JUNS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jupiter Neurosciences(JUNS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jupiter Neurosciences,JUNS,Jupiter Neurosciences股票,Jupiter Neurosciences股票老虎,Jupiter Neurosciences股票老虎国际,Jupiter Neurosciences行情,Jupiter Neurosciences股票行情,Jupiter Neurosciences股价,Jupiter Neurosciences股市,Jupiter Neurosciences股票价格,Jupiter Neurosciences股票交易,Jupiter Neurosciences股票购买,Jupiter Neurosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jupiter Neurosciences(JUNS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jupiter Neurosciences(JUNS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}